Citations

Clear

9383 citation(s) found for "Thomas, PS".

A Multicenter Comparison of CRH versus DDAVP Stimulation Responses in Inferior Petrosal Sinus Sampling for Cushing’s Disease
Karsy, Michael, Silverstein, Julie , Evans, James J., Collopy, Sarah , Kelly, Dan, Fernandez‐Miranda, Juan C. , Pacione, Donato , Bergsneider, Marvin , Zada, Gabriel , Kshettry, Varun R. , Wu, Kyle C., Benjamin, Carolina , Catalino, Michael P. , Zwagerman, Nathan T. , Little, Andrew S. , Yuen, Kevin Choong Ji, ITorok, Ildiko, Gardner, Paul A. , Karsy, Michael , Karsy, Michael , Kim, Albert Sungsoo , Rennert, Robert C , Couldwell, William T. , Barkhoudarian, Garni , Kim, Won Bae , Chicoine, Michael , Gompel, Jamie J. Van , Mamelak, Adam N. , Yuen, Kevin C.J.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803037 Get It

Cumulative Excess Body Mass Index and MGUS Progression to Myeloma
Liu, Lawrence , Grandhi, Nikhil , Thomas, Theodore, Schoen, Martin W. , Carson, Kenneth R. , Vachon, Celine M. , Janakiram, Murali , Ji, Mengmeng , Vachon, Celine, Liu, Lawrence , Janakiram, Murali , Wang, Mei , Proskuriakova, Ekaterina , Sanfilippo, Kristen , Visram, Alissa , Vachon, Celine M. , Colditz, Graham A. , Chang, Su‐Hsin

Mayo Clinic

JAMA Network Open | February 7, 2025 | Volume: 8 | Issue: 2 | Pages: e2458585

10.1001/jamanetworkopen.2024.58585 | PMID 39918819 Get It

Importance Obesity is a risk factor associated with multiple myeloma (MM) and its precursor, monoclonal gammopathy of unknown significance (MGUS). However, it is unclear how cumulative exposure to obesity affects the risk of MGUS progression to MM. Objective To determine the association of cumulative exposure to excess body mass index (EBMI), defined as BMI (calculated as weight in kilograms divided by height in meters squared) greater than 25, with risk of MGUS progression to MM. Design, Setting, and Participants This cohort study included patients with MGUS, including immunoglobin G, immunoglobin A, or light chain MGUS, from the nationwide US Veterans Health Administration database from October 1, 1999, to December 31, 2021. A published natural language processing–assisted model was used to confirm diagnoses of MGUS and progression to MM. Data were analyzed from February 12 to November 4, 2024. Exposures Cumulative EBMI was calculated by area under the curve of measured BMI subtracting the reference BMI at 25 during the first 3 years after MGUS diagnosis. Main Outcomes and Measures The main outcome was progression from MGUS to MM. Multivariable Fine-Gray time-to-competing-event analyses, with death as the competing event, were used to determine associations. Results The cohort included 22 429 patients with MGUS (median [IQR] age, 70.5 [63.5-77.9] years; 21 613 [96.4%] male), with 8329 Black patients (37.1%) and 14 100 White patients (62.9%). There were 4862 patients (21.7%) with reference range BMI (18.5 to <25), 7619 patients (34.0%) with BMI 25 to less than 30, and 8513 patients (38.0%) with BMI 30 or greater at the time of MGUS diagnosis. Compared with reference range BMI at MGUS diagnosis, patients with BMI 25 to less than 30 (adjusted hazard ratio [aHR], 1.17; 95% CI, 1.03-1.34) or 30 or greater (aHR, 1.27; 95% CI, 1.09-1.47) at MGUS diagnosis had higher risk of progression to MM. In patients with reference range BMI at MGUS diagnosis, each 1-unit increase of EBMI per year was associated with a 21% increase in progression risk (aHR, 1.21; 95% CI, 1.04-1.40). However, for patients with BMI 25 or greater at MGUS diagnosis, the incremental risk associated with cumulative EBMI exposure was not statistically significant. Conclusions and Relevance This cohort study found that, for patients with BMI 18.5 to less than 25 at the time of MGUS diagnosis, cumulative exposure to BMI 25 or greater was associated with an increased risk of progression. These findings suggest that for these patients, maintaining a healthy and stable weight following MGUS diagnosis may prevent progression to MM.
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐ GemOx : A Multicenter Cohort Study
Yamshon, Samuel , Koff, Jean L. , Larson, Melissa C. , Kahl, Brad S. , Casulo, Carla , Lossos, Izidore S. , Haddadi, Sara , Stanchina, Michele , Chihara, Dai , Ayers, Amy , Khurana, Arushi , Nowakowski, Grzegorz S. , Reicks, Tanner W., Cohen, Jonathon B. , Martin, Peter , Li, Jia , Shewade, Ashwini, Batlevi, Connie Lee , Lo‐Rossi, Andrea, Fox, David , Masaquel, Anthony, Mun, Yong, Flowers, Christopher R. , Habermann, Thomas , Wang, Yucai , Khurana, Arushi , Nowakowski, Grzegorz S , Farooq, Umar , Link, Brian K , Cohen, Jonathon B , Li, Jia , Shewade, Ashwini , Batlevi, Connie L , Lo-Rossi, Andrea , Fox, David , Masaquel, Anthony , Cerhan, James R , Maurer, Matthew , Kahl, Brad S , Koff, Jean L , Chihara, Dai , Casulo, Carla , Larson, Melissa C , Habermann, Thomas M. , Wang, Yucai , Link, Brian K. , Cerhan, James R. , Maurer, Matthew J. , Nastoupil, Loretta J.

Mayo Clinic

American Journal of Hematology | February 7, 2025 | Volume: 100 | Issue: 4 | Pages: 606-615

10.1002/ajh.27630 | PMID 39918101 Get It

ABSTRACT Rituximab, gemcitabine, and oxaliplatin (R‐GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), but there are limited real‐world data. In a multicenter retrospective study from a cohort of eight US academic centers (LEO CReWE), we evaluated 183 patients with R/R DLBCL and high‐grade B cell lymphoma treated with R‐GemOx, including subgroups treated without intent for consolidation with autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T cell therapy ( n = 100), those utilizing R‐GemOx as a bridge to ASCT or CAR T ( n = 83), and those aged 70 and older ( n = 71). Overall response rates (ORRs) for all patients treated with R‐GemOx were 45% with a complete response (CR) rate of 29%. The median event‐free survival (EFS) was 2.3 months, and the median overall survival (OS) was 13.5 months. Patients receiving R‐GemOx without intent for ASCT or CAR T had ORR and CR rates of 33% and 18%, respectively, with median EFS and OS of 2.0 and 9.5 months, respectively. Patients receiving R‐GemOx as a bridge to ASCT or CAR T had ORR and CR rates of 57% and 36%, respectively, with median EFS and OS of 3.5 and 17.4 months, respectively. Patients receiving R‐GemOx aged 70 and older had ORR and CR rates of 53% and 33%, respectively, with median EFS and OS of 2.2 and 13.9 months, respectively. These data provide a benchmark for R‐GemOx in the rapidly evolving landscape of R/R DLBCL therapies.
Efficacy and safety of preoperative embolization in surgical treatment of brain arteriovenous malformations: a multicentre study with propensity score matching
Salim, Hamza , Hamdan, Dawoud, Adeeb, Nimer , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S. , Dmytriw, Adam A. , Ataoglu, Cagdas , Erginoğlu, Ufuk , Naamani, Kareem El, Sheehan, Jason P. , Ironside, Natasha , Gummadi, Sanjeev, Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Sen, Rajeev , Başkaya, Mustafa K. , Tjoumakaris, Stavropoula , Atallah, Elias , Riina, Howard A. , Abushehab, Abdallah, Swaid, Christian, Burkhardt, Jan‐Karl , Starke, Robert M., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Abla, Adib A. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Cochran, Joseph, Pukenas, Bryan , Smith, Edward R. , Moehlenbruch, Markus, Alaraj, Ali , Patel, Aman B. , Yedavalli, Vivek , Cuellar, Hugo H, Lawton, Michael T. , Guthikonda, Bharat , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S , Dmytriw, Adam A , Essibayi, Muhammed Amir , Alwakaa, Omar , Griessenauer, Christoph J , Jabbour, Pascal , Altschul, David J , Koch, Matthew J , Chen, Peng R , Orbach, Darren B , Alaraj, Ali , Yedavalli, Vivek S , Abla, Adib , Salim, Hamza , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Hamdan, Dawoud , Kandregula, Sandeep , Abdelsalam, Ahmed , Kondziolka, Douglas , Naamani, Kareem El , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Rezai, Arwin, Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Jabbour, Pascal , Sekhar, Laligam N. , Levitt, Michael R. , Blackburn, Spiros , Choudhri, Omar , Orbach, Darren B. , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Wintermark, Max , Savardekar, Amey Rajan , Morcos, Jacques J.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | February 6, 2025 | Volume: 96 | Issue: 8 | Pages: 766-774

10.1136/jnnp-2024-334974 | PMID 39915091 Get It

Background Brain arteriovenous malformations (AVMs) are abnormal connections between feeding arteries and draining veins, associated with significant risks of haemorrhage, seizures and other neurological deficits. Preoperative embolization is commonly used as an adjunct to microsurgical resection, with the aim of reducing intraoperative complications and improving outcomes. However, the efficacy and safety of this approach remain controversial. Methods This study is a subanalysis of the Multicenter International Study for Treatment of Brain AVMs consortium. We retrospectively analysed 486 patients with brain AVMs treated with microsurgical resection between January 2010 and December 2023. Patients were divided into two groups: those who underwent microsurgery alone (n=245) and those who received preoperative embolization, followed by microsurgery (n=241). Propensity score matching was employed, resulting in 288 matched patients (144 in each group). The primary outcomes were rates of complete AVM obliteration and functional outcomes (measured by the modified Rankin Scale (mRS)). Secondary outcomes included complication rates, mortality, hospital length of stay and postsurgical rupture. Results After matching, the complete obliteration rate was 97% with no significant difference between the microsurgery-only group and the preoperative embolization group (p=0.12). The proportion of patients with an mRS score of 0–2 at the last follow-up was similar in both groups (83% vs 84%; p=0.67). The median hospital stay was significantly longer for the embolisation group (9 days vs 7 days; p=0.017). Complication rates (24% vs 22%; p=0.57) and mortality rates (4.9% vs 2.1%; p=0.20) were comparable between the two groups. No significant differences were observed in postsurgical rupture, recurrence or retreatment rates. Conclusions In this large multicentre study, preoperative embolization did not significantly improve AVM obliteration rates, functional outcomes or reduce complications compared with microsurgery alone.
Recognition of the Large Ambulatory C2D Stage of Advanced Heart Failure—A Call to Action
Lala, Anuradha , Stewart, Garrick C. , Wong, Renee , Morris, Alanna A. , Breathett, Khadijah , Cogswell, Rebecca , Colvin, Monica , Drakos, Stavros , Gelfman, Laura P. , Kanwar, Manreet , Kittleson, M. , Lewis, Eldrin F. , Ogunniyi, Modele O. , Pandey, Ambarish , Rogers, Joseph G. , Teuteberg, Jeffrey J. , Valantine, Hannah A. , Dixon, Debra , Hanff, Thomas C. , Hsiao, Stephanie, McCormick, Amanda D. , Fenton, Kathleen N. , Longacre, Lisa Schwartz, Shanbhag, Sujata M., Taddei‐Peters, Wendy C. , Stevenson, L W, Dunlay, Shannon M. , Kanwar, Manreet K , Breathett, Khadijah , McCormick, A , Colvin, Monica M , Pinney, Sean P , McIlvennan, Colleen Kelley , Pagani, Francis D. , Allen, Larry A. , Cowger, Jennifer , Kiernan, Michael S. , Moazami, Nader , Pandey, Ambarish , Schumacher, Kurt R. , Slaughter, Mark S. , Tedford, Ryan J. , DeFilippis, Ersilia M. , Golbus, Jessica R , Gulati, Gaurav , Lewsey, Sabra C , Nayak, Aditi , Stevenson, Lynne W.

Mayo Clinic

JAMA Cardiology | February 5, 2025 | Volume: 10 | Issue: 4 | Pages: 391

10.1001/jamacardio.2024.5328 | PMID 39908057 Get It

ImportanceThe advanced ambulatory heart failure (HF) population comprises patients who have progressed beyond the pillars of recommended stage C HF therapies but can still find meaningful life-years ahead. Although these patients are commonly encountered in practice, national databases selectively capture the small groups accepted for heart transplant listing or left ventricular assist devices. The epidemiology, trajectories, and therapies for other ambulatory patients with advanced HF are poorly understood.ObservationsIn December 2022, the National Heart, Lung and Blood Institute convened a team of experts to identify knowledge gaps and research priorities for the ambulatory population with limiting daily symptoms and transition toward refractory end-stage D HF, designated as stage C2D. This article summarizes the findings from that 3-day workshop. Workshop participants surveyed the initial challenges and knowledge gaps for (1) recognition of ambulatory C2D HF, (2) estimation of the magnitude of the affected population and identifiable subpopulations, and (3) physiologic phenotypes, such as low cardiac output, right HF, cardiorenal syndromes, congestive hepatopathy and frailty, which offer distinct targets for existing and emerging therapies. Social drivers of HF and patient preferences for quality/length of survival were highlighted as essential modifiers for personalization of therapies.Conclusions and RelevanceTen key points summarized workshop findings, with target cohorts for study proposed as a crucial next step. This workshop summary is intended as a call for action to address knowledge gaps and develop new strategies to improve outcomes in the large ambulatory population with C2D HF.
Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion
Goyal, Mayank , Möhlenbruch, Markus , Nimjee, Shahid M. , Buck, Brian , Kennedy, James , Zhang, Liqun , Hametner, Christian , Nardai, Sándor , Zafar, Atif , Diprose, William K. , Vatanpour, Shabnam , Stebner, Alexander, Bosshart, Salome , Uchida, Kazutaka , Ryckborst, Karla J., Fahed, Robert, Hu, Sherry , Zaidi, Syed , Lee, Vivien , Teal, Rachel, Trivedi, Anurag , Ogungbemi, Ayokunle, Orosz, Péter , Abdalkader, Mohamad , Taschner, Christian , Tarpley, Jason , Poli, Sven , Sahlas, Demetrios J. , Burns, Paul , Marigold, Richard , Amole, Adewumi, Field, Thalia S. , Settecase, Fabio , Lenzsér, Gábor, Asdaghi, Negar , Lobotesis, Kyriakos , Siddiqui, Adnan H. , Berrouschot, J., Ebersole, Koji , Schneider, Hauke , Mandzia, Jennifer, Klostranec, Jesse , Jadun, Changez, Patankar, Tufail , Sauvageau, Eric , Lenthall, Robert , Peeling, Lissa, Budzik, Ronald F. , Lee, Seon-Kyu, Perry, Richard , Hlaing, Thant , Singh, Paul, Hill, Michael D. , Vakharia, Kunal , Harston, George , Möhlenbruch, Markus A , Nimjee, Shahid M , Buck, Brian H , Kennedy, James , Zhang, Liqun , Hametner, Christian , Diprose, William , Vatanpour, Shabnam , Stebner, Alexander , Bosshart, Salome , Singh, Nishita , Hu, Sherry X , Vollherbst, Dominik F , Lee, Vivien H , Rempel, Jeremy L , Teal, Rachel , Trivedi, Anurag , Bode, Felix J , Abdalkader, Mohamad , Poli, Sven , Singh, Ravinder-Jeet , Lopez, George , Schaafsma, Joanna D , Marigold, Richard , Field, Thalia S , Settecase, Fabio , Ortega-Gutierrez, Santiago , Mokin, Maxim , Ebersole, Koji , Schneider, Hauke , Yoo, Albert J , Klostranec, Jesse , Lenthall, Robert , Huynh, Thien , Budzik, Ronald , Levitt, Michael R , Jahromi, Babak S , Hill, Michael D , Siddiqui, Adnan H , Ospel, Johanna M. , Ganesh, Aravind , Dowlatshahi, Dar , Volders, David , Jumaa, Mouhammad , Booth, Thomas Calvert , Shankar, Jai , Dorn, Franziska , Sebastian, Ivy Anne , Fahed, Robert , Lynch, Jeremy , Bode, Felix J. , Pham, Mirko , Leacy, Reade De , Chen, Michael , Reich, Arno , Swartz, Richard H. , Yoo, Albert J. , Huynh, Thien , Makalanda, Levansri , Levitt, Michael R. , Jahromi, Babak S. , Demchuk, Andrew M.

Mayo Clinic

New England Journal of Medicine | February 5, 2025 | Volume: 392 | Issue: 14 | Pages: 1385-1395

10.1056/nejmoa2411668 | PMID 39908448 Get It

The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset
Liu, Haiyan , Marsh, Thomas W. , Shi, Xinyu , Bowling, Kevin M. , Ziegemeier, Ellen , Wang, Guoqiao , Cao, Yuchen , Aristel, Alisha, Li, Jessie, Dickson, Alexa , Perrin, Richard J. , Goate, Alison , Fernández, María Victoria , Day, Gregory S. , Doering, Michelle , Daniels, Alisha , Hassenstab, Jason , Supnet, Charlene , Xiong, Chengjie , Berman, Sarah , Ryan, Natalie S. , Huey, Edward D. , Noble, James M. , Roh, Jee Hoon , Laske, Christoph , Sánchez‐Valle, Raquel , Méndez, Patricio Chrem, Chhatwal, Jasmeer P. , Farlow, Martin R. , Xiong, Chengjie , Gordon, Brian A , Ibanez, Laura , Vöglein, Jonathan , Roh, Jee Hoon , Ikeuchi, T , Sánchez-Valle, Raquel , Chhatwal, Jasmeer , Xiong, Chengjie , Rosa-Neto, Pedro , Schofield, Peter R , Bateman, Randall J , Cruchaga, Carlos , Day, Gregory S , Hassenstab, Jason , Fernandez, Maria , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Noble, James M , Renton, Alan , Gordon, Brian A. , Benzinger, Tammie L.S. , Allegri, Ricardo , Fox, Nick C. , Vöglein, Jonathan , Jucker, Mathias , Ikeuchi, Takeshi , Schofield, Peter R. , Lee, Jae‐Hong , Levey, Allan I. , Lopera, Francisco Javier , Martins, Ralph N. , Niimi, Yoshiki , Bateman, Randall J. , Karch, Celeste M. , McDade, Eric , Llibre‐Guerra, Jorge J.

Mayo Clinic

Brain | February 4, 2025 | Volume: 148 | Issue: 7 | Pages: 2429-2440

10.1093/brain/awaf038 | PMID 39903689 Get It

Abstract We present a comprehensive global analysis of genetic variants associated with autosomal-dominant Alzheimer’s disease (ADAD). A total of 550 variants in the APP, PSEN1 and PSEN2 genes were identified, of which 279 were classified as pathogenic or likely pathogenic based on American College of Medical Genetics and Genomics and the Association for Molecular Pathology criteria, utilizing data from the Dominantly Inherited Alzheimer Network (DIAN), literature and public databases. Symptomatic age at onset (AAO) data were estimated for 227 of these variants, allowing detailed characterization of their frequency, pathogenicity and AAO. Importantly, 226 variants met eligibility criteria for inclusion in disease-modifying clinical trials. Furthermore, we demonstrated the predictive value of mean variant AAO and parental AAO in predicting symptomatic AAO, validated against converters who became symptomatic during follow-up in the DIAN Observational Study. This dataset provides critical insights into the global landscape of ADAD and reveals the genetic and AAO heterogeneity of ADAD variants while refining variant trial eligibility criteria.
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Wood, Cameron , Lyniv, Liliana, Isaacs, James M, Kaufman, Jacob M., Oduah, Eziafa , Clarke, Jeff, Crawford, Jeffrey, Stinchcombe, Thomas E. , Tong, Betty , Wigle, Dennis A. , Dragnev, Konstantin H. , Antonia, Scott , Ready, Neal , Wigle, Dennis, Ready, Neal , Wood, Cameron , Isaacs, James , Wang, Xiaofei , Gu, Lin, Weinhold, Kent J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | February 4, 2025 | Volume: 13 | Issue: 2 | Pages: e010395

10.1136/jitc-2024-010395 | PMID 39904561 Get It

Background Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC. Methods This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, clinical stage IB to IIIA NSCLC. Patients received two doses of 200 mg pembrolizumab, surgery, standard adjuvant chemotherapy, followed by four doses adjuvant pembrolizumab. The primary objective of this study was to determine surgical feasibility rate, and secondary objectives are pathological response rate, treatment adverse events, efficacy data, and exploratory analysis of biomarkers. Results 30 patients initiated perioperative pembrolizumab, and 25 completed tumor resection. At median follow-up of 59 months after surgical resection, seven patients had disease progression, while six had died representing. A 5-year progression-free survival (PFS) from time of surgery was 72.0% (56.4%–91.9%) and overall survival (OS) from time of surgery was 75.8% (60.7%–94.7%). Major pathological response (MPR) was found in seven tumors (28%) including two complete responses (4%). Across all treated patients, four receiving neoadjuvant and four receiving adjuvant pembrolizumab experienced treatment-related adverse events of grade 3 or higher with no grade 5 events. Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels increased across our patient cohort over time from baseline until postsurgery and remained elevated at the end of treatment. There was a significant difference between mean plasma PCSK9 levels for patients with MPR versus all other patients on study when checked postoperatively. Conclusions Perioperative pembrolizumab was safe and effective with promising MPR rate, PFS, and OS.